Compare Incyte Corporation (INCY) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Jabil Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Jabil Inc trades at $365.21 (market cap $37.37B). The key difference: Jabil Inc is the larger of the two by market cap, and Jabil Inc pays a 0.09% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | JBL | |
|---|---|---|
Market Cap | $24.54B | $37.37B |
Sector | Health | Technology |
52-Week High | $129.93 | $385.50 |
52-Week Low | $81.61 | $192.49 |
Enterprise Value | $20.04B | $39.90B |
Dividend Yield | — | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
JBL trades at $368.37, up 9.43% with strong bullish momentum driven by AI infrastructure demand and recent earnings beats. The stock shows robust technical strength with moving averages signaling buy and price approaching resistance at $371. Fundamentally, revenue growth accelerated to $33.6B in 2026 with net profit margin improving to 2.56%, though valuation multiples remain elevated with P/E at 44.63.
Outlook remains positive with analyst consensus target of $448.29 (22% upside) and 50% buy ratings. Key opportunities include projected AI revenue growth to $20B+ by 2027, while risks include competitive pressures and the stock's premium valuation. Recent UBS upgrade to Buy highlights multi-year AI growth cycle potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
